Skip to main content
Updates in Clinical Dermatology

Exanthematous Drug Eruptions

Publication ,  Chapter
Gabel, C; Kroshinsky, D
January 1, 2022

Exanthematous (also known as morbilliform) drug reactions are one of the most common cutaneous adverse drug reactions (CADRs). Clinically, exanthematous reactions appear as erythematous macules and papules, sometimes accompanied by pruritus and low-grade fever, appearing days to weeks after culprit drug administration. While the pathogenesis of exanthematous drug reactions remains to be fully elucidated, it is thought to be a form of delayed T-cell hypersensitivity reaction. The list of offending agents is broad, and almost any medication may cause an exanthematous drug eruption. However, antibiotics are common offending agents. Diagnosis is clinical; identifying warning signs and symptoms of a more severe cutaneous adverse reaction is critical. Treatment of exanthematous drug eruptions is primarily supportive, providing symptomatic relief if symptoms are present. Further study is indicated for learning more about the pathophysiological mechanisms, role of systemic therapy, and role of desensitization for future use of the causative medications.

Duke Scholars

DOI

Publication Date

January 1, 2022

Volume

Part F5711

Start / End Page

103 / 110
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gabel, C., & Kroshinsky, D. (2022). Exanthematous Drug Eruptions. In Updates in Clinical Dermatology (Vol. Part F5711, pp. 103–110). https://doi.org/10.1007/978-3-031-09388-3_7
Gabel, C., and D. Kroshinsky. “Exanthematous Drug Eruptions.” In Updates in Clinical Dermatology, Part F5711:103–10, 2022. https://doi.org/10.1007/978-3-031-09388-3_7.
Gabel C, Kroshinsky D. Exanthematous Drug Eruptions. In: Updates in Clinical Dermatology. 2022. p. 103–10.
Gabel, C., and D. Kroshinsky. “Exanthematous Drug Eruptions.” Updates in Clinical Dermatology, vol. Part F5711, 2022, pp. 103–10. Scopus, doi:10.1007/978-3-031-09388-3_7.
Gabel C, Kroshinsky D. Exanthematous Drug Eruptions. Updates in Clinical Dermatology. 2022. p. 103–110.

DOI

Publication Date

January 1, 2022

Volume

Part F5711

Start / End Page

103 / 110